Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Date publication

janvier 2017

Journal

Lancet (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27932229

Résumé

There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment. We aimed to assess the efficacy and safety of regorafenib in patients with HCC who have progressed during sorafenib treatment.

Mots clés

Aged, Antineoplastic Agents, adverse effects, Carcinoma, Hepatocellular, drug therapy, Double-Blind Method, Female, Humans, Kaplan-Meier Estimate, Liver Neoplasms, drug therapy, Male, Middle Aged, Niacinamide, analogs & derivatives, Phenylurea Compounds, adverse effects, Pyridines, adverse effects, Treatment Outcome

Référence

Lancet. 2017 01;389(10064):56-66